
|Videos|September 22, 2022
Dr. Parker on current role of FDA-approved PSMA-PET imaging agents in clinical practice
Author(s)Urology Times staff
Advertisement
Currently there are 2 FDA-approved, commercially available PSMA-PET imaging agents, which are Gallium 68 PSMA-11 (Ga 68 PSMA-11) and piflufolastat F 18 (Pylarify). In this video, William P. Parker, MD, discusses their approved indications and current role in the prostate cancer paradigm. Parker is a practicing urologist at The University of Kanas Health System and an assistant professor at the University of Kansas Medical Center.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












